Why health economics is becoming ever more important in the industry

Pharmaceutical Journal

Volumn 282, Issue 7542, 2009, Pages 255-256

  Carroll, Stuart ^b   Carroll, Ross ^a  

^a ABBOTT LABORATORIES   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT; HEALTH ECONOMICS; POLICY; REIMBURSEMENT; RISK MANAGEMENT; SHORT SURVEY;

EID: 77955874349     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. PricewaterhouseCoopers. Pharma 2020: The vision. Which path will you take? Available at: www.pwc.com (accessed 21 January 2009).
2. Sorenson C, Drummond M, Kavavos P, McGuire A. National Institute for Health and Clinical Excellence: how does it work and what are the implications for the US? London: London School of Economics; 2008.
3. Carroll S. NHS drug availability: an evaluation of the National Institute for Health and Clinical Excellence, Bow Group Official Policy Paper. January 2008. Available at www.bowgroup.org (accessed 21 January 2009).
4. The National Institute for Health and Clinical Excellence. A guide to NICE. London: NICE; 2005.
5. House of Commons Health Committee, National Institute for Health and Clinical Excellence: First Report of Session 2007-08, Volume 1, 17 December 2007.
6. Carroll S, Horsfall L. Are the winds of change blowing through NICE? UBC Evidence Matters 2008;14(3):1-4.
7. Carroll S. Pricing of pharmaceuticals in the UK: implications of reform to the Pharmaceutical Price Regulation Scheme (PPRS), UBC Evidence Matters 2008;14(1):8-10.
8. Collier, J. Parliamentary review asks NICE to do better still. BMJ 2008;336:56-57.
9. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme: an OFT market study. London: OFT; 2007.
10. Association of the British Pharmaceutical Industry. Annual review 2004. London: ABPI; 2005.
11. Claxton K. OFT, VBP: QED? Health Economics 2007;16:545-58.
12. Carroll S, O'Donohoe P. Update on changes to the pricing of UK pharmaceuticals, UBC Evidence Matters, October 2008, Volume XIV, Issue 3: 6-7.
13. Lansley A. Nice doesn't have to be nasty. The Daily Telegraph. 10 September 2008
14. British Telecommunications. Pharma futurology: joined up healthcare - 2016 and beyond; 2007.